Barron's lists USD 7.00 target for Oramed Pharmaceuticals stock
Published on 10/17/2026 at 21:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTarget and trading dates
- Barron's average target was USD 7.00 on September 22, 2026, 72.00 percent above the Nasdaq price.
- Oramed's valuation multiple was 0.99 on October 16, 2026.
- Oramed Pharmaceuticals stock cost USD 4.07 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, 2.63 percent below the prior close of October 15, 2026.
- Oramed's next earnings date is November 12, 2026.
Barron's listed a USD 7.00 average target from one rating for Oramed Pharmaceuticals on September 22, 2026. That target stood 72.00 percent above the Nasdaq price of USD 4.07 on October 16, 2026 at 4:00 p.m. ET. Oramed Pharmaceuticals is listed on Nasdaq under ORMP, according to Barron's.
Valuation multiple was 0.99
The company's price-to-earnings ratio was 0.99 on October 16, 2026, while its market capitalization stood at USD 169.3 million. The valuation data place Oramed among small biotechnology companies, with the ratio providing a compact measure of the earnings value assigned by the market.
Price position on October 16
Oramed's Nasdaq price of USD 4.07 was USD 0.11 below the prior close of USD 4.18 on October 15, 2026. Trading volume reached 277,084 shares on October 16, 2026, against an average volume of 188,225 shares. The 52-week range was USD 2.09 to USD 5.47, leaving the price USD 1.40 below the high and USD 1.98 above the low.
On June 25, 2026, Oramed released a shareholder letter covering its index inclusion, the repayment of a Scilex loan and its balance sheet. The company published that update on its investor-relations page, Oramed Pharmaceuticals.
Valuation and November date
Oramed's next earnings date is November 12, 2026, according to ToAlpha. The date gives investors a defined calendar point after the October 16 price of USD 4.07 and the USD 7.00 average target cited by Barron's.
Comparison with peers
Oramed Pharmaceuticals (Nasdaq, USD): minus 2.63 percent, P/E 0.99, market capitalization USD 169.3 million
Viking Therapeutics (Nasdaq, USD): minus 8.04 percent, P/E minus 5.40, market capitalization USD 3.2 billion
Precigen (Nasdaq, USD): minus 11.26 percent, P/E minus 5.59, market capitalization USD 2.3 billion
Trading frame after October 16
The price remains materially below the 52-week high while the analyst target sits above the latest Nasdaq quotation. The next dated corporate checkpoint is the November 12, 2026 earnings release.
Oramed Pharmaceuticals stock was at USD 4.07 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, 2.63 percent below the prior close of October 15, 2026.
Market context: Market report S&P 500.
